Question 1

What is Fingolimod?

Accepted Answer

Fingolimod is a medication classified as a sphingosine 1-phosphate receptor modulator. It functions by sequestering specific white blood cells, called lymphocytes, within the lymph nodes to prevent them from circulating freely throughout the body.

By keeping these immune cells out of the brain and spinal cord, the medication helps minimize the destruction of the protective coating surrounding nerve fibers. This action helps limit the overall inflammatory response within the central nervous system.

Question 2

What is Fingolimod used for?

Accepted Answer

Fingolimod is used to treat relapsing forms of multiple sclerosis .

Question 3

How does Fingolimod work?

Accepted Answer

Mechanism of Action

Fingolimod is classified as a sphingosine 1-phosphate (S1P) receptor modulator. Its primary function is to regulate the movement of lymphocytes, which are white blood cells that play a key role in the body's immune response.

In multiple sclerosis, the immune system attacks the myelin sheath, the protective covering of the nerves. Fingolimod interferes with this process through the following mechanisms:

Lymphocyte Retention: The medication binds to specific receptors on the surface of white blood cells. This action signals the cells to stay within the lymph nodes rather than entering the bloodstream.

Reduced Central Nervous System Entry: Because the white blood cells are sequestered in the lymph nodes, there are fewer of them available to cross the blood-brain barrier.

Protection of Nerve Fibers: By limiting the number of inflammatory cells that reach the brain and spinal cord, the drug helps prevent the immune-mediated attacks that lead to nerve damage and MS relapses.

It is important to note that fingolimod does not kill the white blood cells; it simply changes where they are located in the body. Once the medication is stopped, these cells eventually begin to circulate normally again.

Question 4

What are the brand names for Fingolimod?

Accepted Answer

Fingolimod is sold under the brand name Gilenya .

Question 5

What are the active ingredients in Fingolimod?

Accepted Answer

The active ingredient in Fingolimod is fingolimod .

Question 6

What are the side effects of Fingolimod?

Accepted Answer

Common side effects of Fingolimod may include:

headache

diarrhea

cough

and others

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Fingolimod?

Accepted Answer

Fingolimod belongs to the sphingosine 1-phosphate receptor modulator drug class.

Question 8

What is the dosage of Fingolimod and how do I take it?

Accepted Answer

Administration

Fingolimod is taken by mouth as a capsule. It is typically taken once daily. You may take it with or without food, but it is helpful to take it at the same time each day.

Swallow the capsule whole. Do not crush, chew, or break the capsule before swallowing.

Your first dose will usually be given in a medical facility where a healthcare professional can monitor you for several hours.

Missed Doses and Interruptions

If you miss a dose, do not take the missed dose. Call your doctor right away for instructions on when to take your next dose. Do not take extra medicine to make up for a missed dose.

If you stop taking this medication for any period of time, you may need to be monitored again by a healthcare professional when you restart. Do not stop taking fingolimod without talking to your doctor first.

Question 9

Is Fingolimod safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Fingolimod can cause harm to a developing fetus. Research in animals has shown that the medication may lead to birth defects or pregnancy loss. Because of these risks, women who are able to become pregnant should use effective contraception while taking fingolimod and for at least two months after the last dose.

If pregnancy occurs during treatment or within two months after stopping fingolimod, a healthcare provider should be contacted immediately. There is a pregnancy registry available to monitor the health of both the mother and the baby for those exposed to the drug during pregnancy.

Breastfeeding

It is currently unknown whether fingolimod passes into human breast milk. However, studies in animals have shown that the drug is excreted in milk. Due to the potential for serious adverse reactions in a nursing infant, breastfeeding is generally not recommended during treatment with fingolimod. Discuss the risks and benefits with a healthcare professional to determine the best course of action.

Question 10

What forms and strengths does Fingolimod come in?

Accepted Answer

Fingolimod is available in the following form:

Oral Capsule: This medication is administered by mouth.

The capsules are designed to be swallowed whole and can be taken with or without food. They are typically supplied in blister packs or bottles to protect the medication from moisture.

Question 11

What is the FDA approval status of Fingolimod?

Accepted Answer

FDA Approval and Indications

Fingolimod was the first oral disease-modifying therapy approved by the FDA for the treatment of relapsing forms of multiple sclerosis (MS). It is currently indicated for adults and pediatric patients 10 years of age and older with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Safety Communications and Monitoring

The FDA requires specific safety protocols for patients starting this medication. Because the first dose can cause a significant decrease in heart rate, patients must be monitored by a healthcare provider for at least six hours after the initial dose. This monitoring includes pulse and blood pressure checks, as well as an electrocardiogram (ECG) before and after the observation period.

In 2018, the FDA issued a safety communication warning that multiple sclerosis symptoms can become significantly worse after stopping fingolimod. This rebound effect can lead to severe disability compared to the patient's condition before or during treatment.

Risk Evaluation and Mitigation Strategy (REMS)

To ensure the benefits of the drug outweigh its risks, the FDA has implemented a Risk Evaluation and Mitigation Strategy (REMS). This program focuses on informing healthcare providers and patients about serious risks, including:

Bradyarrhythmia: Slow or abnormal heart rhythms, especially after the first dose.

Infections: Increased risk of serious infections, including progressive multifocal leukoencephalopathy (PML), a rare brain infection.

Liver Injury: Potential for significant liver damage, identified as a safety signal in FDA adverse event reporting.

Macular Edema: A vision-threatening condition involving swelling in the retina.

Question 12

What should I know about Fingolimod and withdrawal?

Accepted Answer

Risk of Worsening Symptoms

It is important not to stop taking fingolimod without consulting a healthcare provider. When the medication is discontinued, MS symptoms may return. Some patients experience a severe worsening of their condition, sometimes referred to as a rebound effect, which can lead to a higher level of disability than was present before treatment started.

Timing of Withdrawal Effects

Severe exacerbations of MS typically occur within 12 weeks after the last dose of fingolimod is taken, but they have been reported as late as 24 weeks after stopping the medication. In many reported cases, patients did not return to the level of function they had before the symptoms worsened.

Restarting the Medication

If fingolimod treatment is interrupted for more than two weeks, the initial starting procedure must usually be repeated. This includes the six-hour heart rate monitoring required for the very first dose, as the risk of a slow heart rate (bradycardia) returns after the drug has been out of the system for that length of time.

Fingolimod

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Withdrawal Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?